0
Orphan Designations
1
FDA Approvals
Latest: DEXYCU (2018)
0
Active Trials
0
Rare Diseases
0
News (30d)
Quiet
EyePoint Pharmaceuticals US, Inc is a company with 0 orphan drug designations across 0 rare diseases, including 1 FDA-approved therapy.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
No pipeline data available yet.